AstraZeneca’s US Medical Vice President, Oncology discusses 10 years of Lynparza across eight indications

In an interview with Pharm Exec associate editor Don Tracy, Carlos Doti, vice president and head of medical affairs for the U.S. Oncology business unit, shares his thoughts on Lynparza’s evolution in indications including breast, prostate and pancreatic cancer.